All lobbying filings
ULTRAGENYX PHARMACEUTICAL INC.
ULTRAGENYX PHARMACEUTICAL INC. filed a Q4 report for ULTRAGENYX PHARMACEUTICAL INC. on January 16, 2026.
Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Pharmaceuticals
Filing · LD-2 quarterly report
Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 16, 2026
Expenses
$130,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
4
Lobbying activity
3
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.